These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22184517)

  • 1. The biology of myelodysplastic syndromes: unity despite heterogeneity.
    Raza A; Cruz R; Latif T; Mukherjee S; Galili N
    Hematol Rep; 2010 Jan; 2(1):e4. PubMed ID: 22184517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathology of myelodysplastic syndromes: biology of medullary stromal and hematopoietic cells (review).
    Kitagawa M; Kurata M; Yamamoto K; Abe S; Suzuki S; Umeda S
    Mol Med Rep; 2011; 4(4):591-6. PubMed ID: 21584497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.
    Raza A; Galili N
    Nat Rev Cancer; 2012 Dec; 12(12):849-59. PubMed ID: 23175121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic and molecular abnormalities in myelodysplastic syndrome.
    Nagoshi H; Horiike S; Kuroda J; Taniwaki M
    Curr Mol Med; 2011 Nov; 11(8):678-85. PubMed ID: 21902648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of miR-223 on cellular behaviour in non-5q myelodysplastic syndromes through targeting RPS14.
    Nie Y; Wang S; Yu Y; Zuo X; Xiong B
    Pathology; 2020 Aug; 52(5):552-560. PubMed ID: 32571542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.
    Wu L; Li X; Xu F; Zhang Z; Chang C; He Q
    Eur J Haematol; 2013 Jun; 90(6):486-93. PubMed ID: 23506134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of ribosomal proteins in myelodysplastic syndromes.
    Rinker EB; Dueber JC; Qualtieri J; Tedesco J; Erdogan B; Bosompem A; Kim AS
    J Clin Pathol; 2016 Feb; 69(2):176-80. PubMed ID: 26408650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribosomal protein S14 silencing inhibits growth of acute myeloid leukemia transformed from myelodysplastic syndromes via activating p53.
    Wang L; Luo J; Nian Q; Xiao Q; Yang Z; Liu L
    Hematology; 2014 Jun; 19(4):225-31. PubMed ID: 24074450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyserythropoiesis of myelodysplastic syndromes.
    Lefèvre C; Bondu S; Le Goff S; Kosmider O; Fontenay M
    Curr Opin Hematol; 2017 May; 24(3):191-197. PubMed ID: 28072603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the molecular pathophysiology of myelodysplastic syndromes.
    Bejar R; Levine R; Ebert BL
    J Clin Oncol; 2011 Feb; 29(5):504-15. PubMed ID: 21220588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular dissection of the 5q deletion in myelodysplastic syndrome.
    Ebert BL
    Semin Oncol; 2011 Oct; 38(5):621-6. PubMed ID: 21943668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.
    Pellagatti A; Hellström-Lindberg E; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Killick S; Fidler C; Cazzola M; Wainscoat JS; Boultwood J
    Br J Haematol; 2008 Jul; 142(1):57-64. PubMed ID: 18477045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
    Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
    Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
    Gorshein E; Weber UM; Gore S
    Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
    [No Abstract]   [Full Text] [Related]  

  • 19. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
    Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
    Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Treatment for Myelodysplastic Syndromes Patients.
    Montoro J; Yerlikaya A; Ali A; Raza A
    Curr Treat Options Oncol; 2018 Oct; 19(12):66. PubMed ID: 30362079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.